The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).
 
Aditya Bardia
Consulting or Advisory Role - Genentech; Immunomedics; Novartis
 
Noshir Anthony Dacosta
No Relationships to Disclose
 
Nashat Y. Gabrail
No Relationships to Disclose
 
Stephen Lemon
No Relationships to Disclose
 
Michael A. Danso
Honoraria - Amgen
 
Haythem Y. Ali
No Relationships to Disclose
 
Ronald Alan Fleming
Employment - Innocrin Pharma
Stock and Other Ownership Interests - Innocrin Pharma
 
Michael R Kurman
Employment - Innocrin Pharma
Stock and Other Ownership Interests - Innocrin Pharma
 
Joel Robert Eisner
Employment - Innocrin Pharma
Stock and Other Ownership Interests - Innocrin Pharma
 
William Richard Moore
Employment - Innocrin Pharma
Leadership - Innocrin Pharma
Stock and Other Ownership Interests - Innocrin Pharma
 
Ayca Gucalp
Research Funding - Innocrin Pharma; Pfizer
 
Tiffany A. Traina
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Genentech/Roche; Halozyme; Medivation; Mundipharma; Pfizer; Research to Practice
Research Funding - Eisai; Medivation; Novartis; Pfizer